市場調査レポート
商品コード
1418732
3Dプリンター用バイオマテリアルインクの世界市場 2023年~2030年Global 3D Printable Biomaterial Ink Market - 2023-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
3Dプリンター用バイオマテリアルインクの世界市場 2023年~2030年 |
出版日: 2024年01月23日
発行: DataM Intelligence
ページ情報: 英文 187 Pages
納期: 約2営業日
|
世界の3Dプリンター用バイオマテリアルインク市場は、2022年に5億6,870万米ドルに達し、2023-2030年の予測期間中にCAGR 18.8%で成長し、2030年には22億5,630万米ドルに達すると予測されています。
世界の3Dプリンター用バイオマテリアルインク市場は、3Dプリントインプラントが整形外科や歯科矯正でますます一般的になるにつれて、再拡大する設定になっています。3Dプリントされた歯科および整形外科インプラントは、さまざまな疾患の治療の標準となっており、生体材料インクの安定した需要源となっています。
世界の3Dプリンター用バイオマテリアルインク市場の長期的な成長可能性は、過去数年間における新たな技術革新や製品発売のペースが低下していることが足かせとなっています。再生医療やバイオインプラントにおける新機軸に対応する新たなイノベーションがなければ、世界市場は成長停滞のリスクに直面します。
再生医療は、主に広範な国際協力により、近年いくつかの重要なブレークスルーを確認しています。新しいバイオ素材から新しい治療薬に至るまで、多くの新しい再生治療が今後数年の間に市場に登場すると予想されます。こうした進歩はすべて、中長期的に3Dプリンター用バイオマテリアルインクの需要拡大につながる可能性が高いです。
ハイドロゲルは、3Dプリンティング用途に理想的であるという既成のニュースから、特に注目されている分野となっています。例えば、中国の上海交通大学第六人民病院の科学者が発表した研究論文によると、ハイドロゲルは複雑な多組織インプラントの制御された3Dプリンティングに適しています。
幹細胞治療は、特に心臓病の治療に対する有望なアプローチのため、活発に研究されているもう一つの主要分野です。2023年12月、米国の主要な病院・研究センターであるメイヨークリニックが発表した新しい調査によると、新しい幹細胞療法は、進行した心不全患者のQOLを大幅に改善することがわかった。
食肉産業に必要な土地や水資源を削減する必要性に後押しされ、実験室で3Dプリントした食肉は、一部の技術系起業家に採用された人気のアイデアでした。しかし、この無名のアイデアは今や主流派の注目を集めており、多くの新興企業がラボ栽培肉の開発に取り組んでいます。
例えば、2023年6月、米国食品医薬品局(USFDA)は、GOOD MeatとUPSIDE Foodsの2つの新興企業に対し、ラボで培養した鶏肉を米国市場で販売する規制上の承認を与えたと発表しました。さらに、2023年12月には、イスラエルの新興企業Steakholderが、3Dプリンターで培養した新しいウナギ肉の開発を発表しました。
バイオマテリアルインクはラボ栽培肉の重要な構成要素であり、インクは印刷工程でバインダーや充填材として使用されます。実験室栽培肉の人気が高まることで、インクメーカーはさまざまな種類の肉により適した新しいタイプの食用インクを開発できるようになり、世界市場の開拓に貢献することになります。
再生医療やバイオインプラントなど、3Dプリント可能な生体材料インクが使用される新興分野は、歴史的に開発期間が長かった。根本的に新しい画期的なイノベーションを生み出すには、数十年とは言わないまでも数年はかかります。さらに、製品が市場で販売されるまでには、規制当局の承認が次々と必要となります。
これが世界市場の成長性を阻害する一貫した要因となっています。新製品はたまにしか市場に出回らないため、印刷可能な生体材料インクの需要が急激に拡大する余地はないです。さらに、需要はほとんどの期間停滞を続けており、生体材料インクメーカーが生産能力拡大に投資する意欲を削いでいます。
Global 3D Printable Biomaterial Ink Market reached US$ 568.7 million in 2022 and is expected to reach US$ 2,256.3 million by 2030, growing with a CAGR of 18.8% during the forecast period 2023-2030.
The global 3D printable biomaterial ink market is setting for renewed expansion as 3D printed implants become increasingly common in orthopedics and orthodontics. 3D Printed dental and orthopedic implants have become standard for the treatment of various ailments, thus providing a steady source of demand for biomaterial ink.
The long term growth potential for the global 3D printable biomaterial ink market is hobbled by declining pace of new innovation and product launches over the past few years. Without new innovations catering to the up and coming breatkthroughs in regenerative medicines and bio implants, the global market faces a risk of stagnating growth.
Regenerative medicine has witnessed several important breakthroughs in recent years, mainly due to extensive international collaboration. From new bio materials to new therapeutic agents, many new regenerative treatments are expected to hit the market during the upcoming years. All these advances are likely to translate into renewed demand growth for 3D printable biomaterial ink over the medium and long term.
Hydrogels have become a particular area of focus, due to their pre-existing news, making them ideal for 3D printing applications. For instance, according to a research paper published by scientists from the Sixth People's Hospital, Shanghai JiaoTong University in China, hydrogels are suitable for controlled 3D printing for complex multi-tissue implants.
Stem cell therapy is another major area that is actively researched, especially due to its promising approach towards the treatment of heart diseases. New research published in December 2023, by the Mayo Clinic, a major U.S.-based hospital and research center, found that new stem cell therapy significantly improved quality of life for patients with advanced heart failure.
Driven by the need to reduce land and water resources required for the convetional meat industry, lab grown, 3D printed meat was a popular idea adopted by a section of tech entrepreneurs. However, this obscure idea has now attracted mainstream attention and many startups are engaged in developing lab grown meat.
For instance, in June 2023, U.S. food and drug administration (USFDA) announced that it had given regulatory approval to two startups, GOOD Meat and UPSIDE Foods, to sell lab grown chicken meat in U.S. market. Furthermore, in December 2023, Steakholder, an Israeli startup, announced the development of its new 3D printed, lab grown eel meat.
Biomaterial ink is an important component of lab grown meat, where the ink is used as a binder and a filler during the printing process. The growing popularity of lab grown meat will allow ink manufacturers to develop new types of edible ink more suitable for different meat types, thus contributing to the growth of the global market.
The emerging fields in which 3D printable biomaterial ink is used such as regenerative medicine and bio implants, have historically had long gestation periods. It takes years, if not decades to create a fundamentally new breakthrough innovation. Furthermore, there are a string of major regulatory approvals that are required before the products are allowed to be sold in the market.
It has been a consistent factor in hobbling the growth potential of the global market. Since a new product only comes on the market once in a while, there is no scope for radical expansion of demand for printable biomaterial ink. Furthermore, demand continues to remain stagnant for most of the time, disincentivizing biomaterial ink manufacturers from investing in capacity expansion.
The global 3D printable biomaterial ink market is segmented based on type, application and region.
Biomedical implants are witnessing radical new innovations and could potentially generate the highest demand for printable biomaterial ink during the forecast period. One of the key advantages of bio implants is that there is low risk of implant rejection and low immunogenicity. Furthermore, depending on the requirement, the bio implant can remain within the patient's body permanently or undergo biodegradation without any risk to the patient's health.
Current biomedical research is focused on expanding the type and materials of bio implants as well as improving the overall process for bio implant manufacturing. As numerous patents get filed and regulatory approvals are obtained, the demand for printable biomaterial inks for implant manufacturing will skyrocket over the upcoming years.
North America is expected to have the highest share within the global 3D printable biomaterial ink market since it has the largest share of startups and research institutions focused on researching emerging biomedical breakthroughs. All of this is made possible by the well-ordained research-oriented academic ecosystem of U.S. universities. Furthermore, many venture capital funds and government agencies generously fund research in hopes of commercializing new breakthroughs.
Several new 3D bio implants have received regulatory approval over the course of 2023 and the future demand for printable biomaterial ink appears to be stable. For instance, in December 2023, U.S. food and drug administration (USFDA) approved Novosis Ortho, a new, 3D printed spine implant designed to accelerate bone recovery in the event of a spinal injury.
Companies are already entering into collaborative partnerships to help develop this emerging market. For instance, in April 2023, Stratasys, a 3D printing solutions provider, signed a partnership agreement with CollPlant, an Israeli-American company specializing in regenerative medicine, to develop 3D printed regenerative breast implants.
The COVID-19 pandemic created several pitfalls and challenges for the global 3D printable biomaterial ink market. First and foremost, the imposition of lockdowns during the initial pandemic period disrupted research work, forcing many companies to delay and extend the launch of new products. Furthermore, uncertainty in global markets prompted many companies to abandon strenuous research areas. A stark reduction in venture capital funding also led to the bankruptcy of some emerging startups.
The difficult market conditions also created many problems for the supply of 3D printable biomaterial ink. Due to its specialist and niche nature, production was already limited before the pandemic and was further restricted since precursor materials were in short supply due to pandemic induced supply chain disruptions. The overall situation has improved in the post-pandemic period; however, the market is still likely to face challenges over the short and medium term.
The Russia-Ukraine will not significantly impact the global 3D printable biomaterial ink market at large. Although the war did cause major short-term volatility in global energy markets due to severe economic sanctions on Russia, the volatility has been priced in and is unlikely to generate major concern. A temporary spike in precursor material prices led to slightly elevated prices for 3D printable biomaterial ink in the short term.
The most direct impact has been on the local 3D printable biomaterial ink markets in Ukraine and Russia. Many Ukrainian scientists fled the war and have continued their research from universities and research institutes in western Europe. Economic sanctions have led to the cessation of exports of biomaterial ink to Russian entities.
However, some Russian institutions have purchased stocks from Chinese suppliers and the grey market to continue research. Many Russian scientists opposing the war have also fled Russia, thus hobbling the long term growth potential of the domestic market due to loss of talented human capital.
The major global players in the market include: 3D Systems, Inc., Stratasys, Evonik Industries AG, Renishaw plc., Formlabs, Envisiontec US LLC, Sandvik AB, EOS, Aspect Biosystems Ltd. and Bio Inx.
The global 3D printable biomaterial ink market report would provide approximately 46 tables, 41 figures and 187 Pages.
LIST NOT EXHAUSTIVE.